Company: NDRA
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001654954-25-003612
Chunk: 513

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 3
Chunk 513
---
 activities:        Depreciation and amortization  46,489   123,726 Fixed assets write off  8,808   24,868 Inventory reserve  2,387,134   138,045 Stock compensation expense  571,924   996,430 Amortization of right of use assets  159,683   151,725 Warrant Expense  7,323,685     Changes in fair value of warrant liability  (3,447,737)    Gain or Loss on Settlement of warrant exercise  (3,076,664)    Changes in operating assets and liabilities:        Decrease in prepaid expenses  255,913   167,360 Decrease in inventory  235,731   (116,193)Decrease in accounts payable and accrued liabilities  (198,867)  (822,258)Decrease in lease liability  (158,698)  (152,228)Net cash used in operating activities  (7,400,547)  (9,548,775)         Cash Flows from Investing Activities        Purchases of fixed assets  (16,000)  (33,884)Proceeds from sale of fixed assets  3,204   9,163 Net cash used in investing activities  (12,796)  (24,721)         Cash Flows from Financing Activities        Proceeds from issuance of common stock  1,148,470   6,483,393 Proceeds from warrant issuances and exercises  6,688,930   1,034,912 Repayment of loan  (28,484)    Net cash provided by financing activities  7,808,917   7,518,305          Net increase (decrease) in cash  395,573   (2,055,191)         Cash, beginning of period  2,833,907   4,889,098          Cash, end of period $3,229,480  $2,833,907          Supplemental disclosures of cash items        Interest paid $31,910  $44,985 Income tax paid $-  $-          Supplemental disclosures of non-cash items